Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting
Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting
Indaptus Therapeutics在ASCO年會上通過Decoy20的1期臨床試驗公佈了新的隊列數據，證實了最初的 “Pulse-Prime” 假設
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.
致力於開創創新的癌症和病毒感染療法的臨床階段生物技術公司Indaptus Therapeutics, Inc.（納斯達克股票代碼：INDP）今天公佈了6月1日在美國臨床腫瘤學會2024年年會上發佈的海報的數據。該會議將於 2024 年 5 月 31 日至 6 月 4 日在芝加哥的味好美廣場舉行，屆時將提供完整數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。